Publications
5898 Results
- Journal / Conference
- ASCO GI Cancers Symposium (January 8 - 10, 2026, San Francisco, CA); J Clin Oncol 44, TPS790(2026); DOI: 10.1200/JCO.2026.44.2_suppl.TPS790
- Year
- 2026
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S2408
S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula
- Journal / Conference
- JAMA Network Open. 2026 Apr 1;9(4):e264901. doi: 10.1001/jamanetworkopen.2026.4901.
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41961500
- PMC
- PMC13069458
- Study Number(s)
- S1714
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714
- Journal / Conference
- Blood Advances 2026 May 8:bloodadvances.2026019616. doi: 10.1182/bloodadvances.2026019616
- Year
- 2026
- Research Committee(s)
- Leukemia
- PMID
- 42101912
- Study Number(s)
- C10403
Long-Term Follow-up of an Intensive Pediatric Regimen for Adolescents/Young Adults with Ph-negative Acute Lymphoblastic Leukemia: 10-year Survival Following CALGB 10403 (Alliance)
- Journal / Conference
- Cancers (Basel). 2026 Jan 25;18(3):373. doi: 10.3390/cancers18030373.
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- 41681846
- PMC
- PMC12896856
- Study Number(s)
- CTSU/A221504
Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study
- Journal / Conference
- Journal for the ImmunoTherapy of Cancer 2026 Feb 11. 14:e012805. doi:10.1136/jitc-2025-012805.
- Year
- 2026
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- 41672597
- Study Number(s)
- S1609
DART/SWOG/NCI phase II anti- CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
- Journal / Conference
- Journal of Clinical Oncology. 2026 June 3 epub. DOI: 10.1200/JCO-25-01896
- Year
- 2026
- Research Committee(s)
- Lung
- PMID
- 42234933
- Study Number(s)
- LUNGMAP
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective from Lung-MAP Investigators
- Journal / Conference
- Annals of Oncology
- Year
- 2026
- Research Committee(s)
- Breast
- PMID
- 13488494
- PMC
- PMC42613139
- Study Number(s)
- S1007
Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER)
- Journal / Conference
- Int J Radiat Oncol Biol Phys. 2026 Jul 28:S0360-3016(26)04066-6.
- Year
- 2026
- Research Committee(s)
- Breast
- PMID
- 42520859
- Study Number(s)
- S1706
Adverse Events in a Randomized Trial Comparing Radiation Therapy With or Without Olaparib for Inflammatory Breast Cancer
- Journal / Conference
- J Natl Cancer Inst . 2026 Jul 15:djag221. doi: 10.1093/jnci/djag221
- Year
- 2026
- Research Committee(s)
- Breast
- PMID
- 42458791
- Study Number(s)
- S1007
Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007)
- Journal / Conference
- NPJ Precision Oncology 2026 Jul 3;10(1):258. doi: 10.1038/s41698-026-01588-7.
- Year
- 2026
- Research Committee(s)
- Genitourinary
- PMID
- 42399473
- PMC
- PMC13332042
- Study Number(s)
- S1314